Was referring to the primary endpoint and sub-populations based on the criteria I specified.
Yes, SE will give an read on MoA. But some, eg hospitalization and long covid issues, are key clinical parameters and these are the sole focus of some very large studies already. Not saying anything will be approvable on first readout but you don't get through 2 interim analysis with that high bar and come out with no efficacy data. And 'cherry picking' efficacy data will be more palatable to all and sundry due to the ridiculously uncontrolled nature of this study.
Analysis of the EAP, page-1067
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.15 |
Change
0.045(4.07%) |
Mkt cap ! $1.313B | |||
| Open | High | Low | Value | Volume |
| $1.08 | $1.16 | $1.08 | $4.681M | 4.170M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 99680 | $1.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.16 | 31000 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |